| 000 | 01372 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250512060659.0 | ||
| 264 | 0 | _c19870605 | |
| 008 | 198706s 0 0 eng d | ||
| 022 | _a0030-2414 | ||
| 024 | 7 |
_a10.1159/000226452 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCraig, J B | |
| 245 | 0 | 0 |
_aAntiemetic therapy in patients treated with high-dose cytosine arabinoside. _h[electronic resource] |
| 260 |
_bOncology _c1987 |
||
| 300 |
_a90-2 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBasal Ganglia Diseases _xchemically induced |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLorazepam _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetoclopramide _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNausea _xchemically induced |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aVomiting _xprevention & control |
| 700 | 1 | _aPowell, B L | |
| 700 | 1 | _aWhite, D R | |
| 700 | 1 | _aCapizzi, R L | |
| 773 | 0 |
_tOncology _gvol. 44 _gno. 2 _gp. 90-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000226452 _zAvailable from publisher's website |
| 999 |
_c3559804 _d3559804 |
||